CHOP-VP16 Chemotherapy and Radiation for Non-Hodgkin's Lymphomas
Author Information
Author(s): H. Kdppler, K.H. Pfliger, I. Eschenbach, R. Pfab, K. Lennert, W. Wellens, M. Schmidt, W.D. Gassel, T. Kolb, R. HafBler, K. Schumacher, G. v. Speth, R. Hollet, K. Havemannt
Primary Institution: Philipps-University, Marburg
Hypothesis
Can a combined treatment of CHOP-VP16 chemotherapy and involved field irradiation improve remission rates in high grade non-Hodgkin's lymphomas?
Conclusion
The study found that the combined treatment resulted in high complete remission rates and significant long-term disease-free survival for patients.
Supporting Evidence
- 82% of patients achieved complete remission after treatment.
- Median survival was 43 months.
- 55% of patients maintained complete remission for up to 68 months.
- Major side effects included alopecia (89%) and nausea/vomiting (76%).
- No therapy-related deaths were reported.
Takeaway
Doctors used a special treatment to help people with a type of cancer called non-Hodgkin's lymphoma, and many of them got better and stayed healthy for a long time.
Methodology
Patients received CHOP-VP16 chemotherapy followed by involved field irradiation, with evaluations after treatment to assess response.
Limitations
The study did not include patients with lymphoblastic NHL aged under 25, and the follow-up period varied.
Participant Demographics
Median age was 56 years, with 65% over 50 and 40% over 60; included both male and female patients.
Statistical Information
P-Value
p<0.002
Statistical Significance
p<0.002
Want to read the original?
Access the complete publication on the publisher's website